000286081 001__ 286081
000286081 005__ 20240229155120.0
000286081 0247_ $$2doi$$a10.3390/cancers15235656
000286081 0247_ $$2pmid$$apmid:38067360
000286081 0247_ $$2pmc$$apmc:PMC10705067
000286081 037__ $$aDKFZ-2023-02657
000286081 041__ $$aEnglish
000286081 082__ $$a610
000286081 1001_ $$0P:(DE-He78)a92f91afa83da73641a4f3abec1d3c6d$$aLi, Xianzhe$$b0$$eFirst author$$udkfz
000286081 245__ $$aPotential of Fecal Carcinoembryonic Antigen for Noninvasive Detection of Colorectal Cancer: A Systematic Review.
000286081 260__ $$aBasel$$bMDPI$$c2023
000286081 3367_ $$2DRIVER$$aarticle
000286081 3367_ $$2DataCite$$aOutput Types/Journal article
000286081 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1702378205_9556$$xReview Article
000286081 3367_ $$2BibTeX$$aARTICLE
000286081 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000286081 3367_ $$00$$2EndNote$$aJournal Article
000286081 500__ $$a#EA:C070#LA:C070#LA:C120#
000286081 520__ $$aCarcinoembryonic antigen (CEA) is more abundant in feces than in serum; however, evidence for the role of fecal CEA (FCEA) in the detection of colorectal cancer (CRC) is limited. We conducted a systematic review of studies that evaluated FCEA for the noninvasive detection and diagnosis of CRC. PubMed and Web of Science were searched for relevant studies published until 18 January 2023. Information on publication year, study design, country, study population characteristics, FCEA and serum CEA (SCEA) concentrations, and diagnostic performance was summarized. Two authors independently extracted data and assessed the risk of bias and applicability of each included study. Seven studies published between 1979 and 2021, all conducted in clinical settings and together involving 399 CRC patients and 889 controls, were identified. Significant differences in FCEA concentrations were observed between CRC and control groups in all studies. Methods for detecting FCEA varied, with the electronic chemiluminescence immunoassay (ECLIA) being used in the most recent studies. Reported sensitivities, specificities, and area under the curves of FCEA ranged from 50.0% to 85.7%, 73.0% to 100.0%, and 0.704 to 0.831, respectively. In direct comparisons, the diagnostic performance of FCEA was better than that of SCEA. The potential role of FCEA as a novel, noninvasive, easily measurable biomarker for the diagnosis of CRC requires further evaluation in screening settings.
000286081 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000286081 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000286081 650_7 $$2Other$$acarcinoembryonic antigen
000286081 650_7 $$2Other$$acolorectal cancer
000286081 650_7 $$2Other$$adiagnosis
000286081 650_7 $$2Other$$astool
000286081 7001_ $$0P:(DE-He78)3fdea8ae87276603a98a327d1937cc50$$aStassen, Lara$$b1
000286081 7001_ $$0P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86$$aSchrotz-King, Petra$$b2$$udkfz
000286081 7001_ $$0P:(DE-He78)ad2dff19f16208697af82eaa31fa9d60$$aZhao, Zitong$$b3$$udkfz
000286081 7001_ $$00000-0002-9155-7415$$aCardoso, Rafael$$b4
000286081 7001_ $$0P:(DE-He78)43ea0369702f56d45fa4a32df9f49aca$$aRaut, Janhavi R$$b5$$udkfz
000286081 7001_ $$0P:(DE-He78)ac7aed57f26354e8a484b5d257f7bada$$aBhardwaj, Megha$$b6$$udkfz
000286081 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b7$$eLast author$$udkfz
000286081 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers15235656$$gVol. 15, no. 23, p. 5656 -$$n23$$p5656$$tCancers$$v15$$x2072-6694$$y2023
000286081 909CO $$ooai:inrepo02.dkfz.de:286081$$pVDB
000286081 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a92f91afa83da73641a4f3abec1d3c6d$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000286081 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3fdea8ae87276603a98a327d1937cc50$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000286081 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000286081 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ad2dff19f16208697af82eaa31fa9d60$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000286081 9101_ $$0I:(DE-588b)2036810-0$$60000-0002-9155-7415$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000286081 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)43ea0369702f56d45fa4a32df9f49aca$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000286081 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ac7aed57f26354e8a484b5d257f7bada$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000286081 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000286081 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000286081 9141_ $$y2023
000286081 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2022$$d2023-10-26
000286081 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-26
000286081 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-26
000286081 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-26
000286081 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-07-31T16:07:06Z
000286081 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-07-31T16:07:06Z
000286081 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-07-31T16:07:06Z
000286081 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2023-07-31T16:07:06Z
000286081 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-26
000286081 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-26
000286081 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-26
000286081 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-26
000286081 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-26
000286081 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-26
000286081 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-26
000286081 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-26
000286081 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2022$$d2023-10-26
000286081 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-10-26
000286081 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-10-26
000286081 9202_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000286081 9202_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000286081 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000286081 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000286081 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000286081 9200_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000286081 980__ $$ajournal
000286081 980__ $$aVDB
000286081 980__ $$aI:(DE-He78)C070-20160331
000286081 980__ $$aI:(DE-He78)C120-20160331
000286081 980__ $$aI:(DE-He78)HD01-20160331
000286081 980__ $$aUNRESTRICTED